Ambu A/S (AMBBY) Stock

About Ambu A/S

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics segmet provides electrodes for cardiology, neurophysiology, and polysomnography. The Visualisation segment includes single-use visualisation devices, which are used in single lung ventilation procedure, or a bedside bronchoscopy procedure in the intensive care unit . The company was founded by Holger Hesse in 1937 and is headquartered in Ballerup, Denmark.

Ambu A/S is headquartered in DK.

Ambu A/S (AMBBY) stock trades at $10.86 with a market capitalization of $2.89B. The stock is valued at a price-to-earnings (P/E) ratio of 41.15, price-to-book of 3.20, price-to-sales of 3.19. Over the past 52 weeks the stock has ranged between $8.55 and $16.78, and currently trades 35.3% below its 52-week high. It pays a dividend yielding 0.55%.

On profitability, Ambu A/S generates a return on equity (ROE) of 7.92%, return on capital employed of 9.95%, an operating margin of 10.71%, a net profit margin of 7.81%.

Official website: www.ambu.com

Ambu A/S by the numbers, 2016–2025

Between 2016 and 2025 Ambu A/S reported revenue of $2.1B rising to $5.7B, a change of +172.8% across 10 years. Compounded, revenue has grown 9.8% a year over five years, 8.6% over three, 5.5% over the last twelve months. Net profit rose to $574.0M.

Operating margin went from 17.1% in 2016 to 13.0% in 2025, a fall of 4.1 percentage points. The most recent net margin is 7.81%. On a trailing twelve-month basis to Mar '26, revenue is $-18.7B and net profit $479.0M.

Borrowings fell from $990.0M to $548.0M, cash on hand is $691.7M, cash from operations was $745.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 5.0% over five years, and was 9.5% in the most recent year.

The share price itself has compounded at -21.5% a year over five years, -7.9% over three, -29.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Ambu A/S (AMBBY) — frequently asked questions